UBS Group restated their sell rating on shares of AstraZeneca (LON:AZN) in a research report report published on Wednesday, ThisIsMoney.Co.Uk reports.
A number of other research firms have also commented on AZN. Credit Suisse Group set a GBX 7,300 ($95.39) price objective on AstraZeneca and gave the stock a buy rating in a research note on Friday, July 26th. Goldman Sachs Group set a GBX 5,500 ($71.87) price objective on AstraZeneca and gave the stock a sell rating in a research note on Tuesday, August 20th. Kepler Capital Markets set a GBX 6,470 ($84.54) price objective on AstraZeneca and gave the stock a buy rating in a research note on Monday, May 13th. Barclays raised their price objective on AstraZeneca from GBX 7,600 ($99.31) to GBX 7,800 ($101.92) and gave the stock an overweight rating in a research note on Friday, August 16th. Finally, Liberum Capital restated a hold rating on shares of AstraZeneca in a research note on Tuesday, August 20th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the company’s stock. AstraZeneca currently has an average rating of Hold and a consensus target price of GBX 6,688.24 ($87.39).
AstraZeneca stock opened at GBX 7,313 ($95.56) on Wednesday. The stock’s fifty day moving average price is GBX 6,885.06 and its two-hundred day moving average price is GBX 6,283.40. AstraZeneca has a one year low of GBX 5,312 ($69.41) and a one year high of GBX 7,479 ($97.73). The company has a debt-to-equity ratio of 144.48, a current ratio of 0.95 and a quick ratio of 0.74. The firm has a market cap of $95.94 billion and a PE ratio of 42.72.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: What is quantitative easing?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.